Research
Hormonal
Semaglutide can be used safely and efficiently in non-diabetic people with excess weight.
Semaglutide may be considered as a treatment option for weight management in non-diabetic patients.
StrongSupportsmedium confidence
Semaglutide is the second marketed glucagon-like peptide 1 receptor agonist that can be used safely and efficiently in non-diabetic people with excess weight.
Why this rating
The claim is based on a review of relevant clinical studies.
Source
Semaglutide and obesity: beyond the nutritional and lifestyle intervention?
Livia Basile et al. · Minerva Endocrinology · 2024
DOI 10.23736/s2724-6507.23.04103-9
reviewCited 7×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →